
Merck KGaA head jumping ship to Lanxess
pharmafile | January 29, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Merck, Merck KGaA, lanxess, zachert
Merck KGaA’s chief financial officer Matthias Zachert is exiting the firm in order to fulfill a chief executive appointment at Lanxess.
Zachert has only been a member of Merck’s board since June 2011 and this bad news for the company was highlighted by its family chairman Frank Stangenberg-Haverkamp.
He said: “We are losing a proven expert who during his three years at Merck has realigned the global finance organisation and played a significant role in our transformation programme ‘Fit for 2018’. We very much regret that Matthias Zachert will leave Merck, but understand his decision in light of the attractive assignment.”
Zachert worked previously with the German-headquartered rubber and thermoplastics group Lanxess as CFO until he left in 2011, and the firm says he is replacing Axel Heitmann, chairman of its board.
Zachert added: “I would like to express my sincere thanks for the trust and good collaboration with the supervisory bodies as well as with my colleagues on the executive board.”
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






